SureTrader SureTrader
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: Mocha Jet, Drugdoctor, joseytheoutlawwales, lasers, John_Langston, IB_
Search This Board:
Last Post: 10/27/2016 2:23:10 PM - Followers: 834 - Board type: Free - Posts Today: 45

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

Elite’s website can be found by going to

How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.


Recent Press Releases:

Oct 21, 2015
Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200

Aug 10, 2015
Elite Pharmaceuticals Reports Record Revenues for First Quarter of Fiscal Year 2016

Aug 3, 2015
Elite Pharmaceuticals Completes Enrollment and Dosing for ELI-200 Phase III Efficacy Trial

Jun 16, 2015
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology

Jun 9, 2015
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200

More information can be found by going to Elite’s investor section:
Highlights From Last Quarter:
Second quarter ending September, 2015
Consolidated revenues for the second quarter of fiscal 2015 was $2.7M, all of which came from Elite's generic operation. An increases of 30% over last quarter's generic revenues. Generic revenue continues to grow with new highs being set  8 out of the 10 last quarters. The cost of revenue for this quarter totals $1.4M, for a gross profit of $1.3M. Overall expenses for the quarter total $5.3M with $4.2M going towards the development of Elite’s proprietary abuse-deterrent opioid product,ELI-200.
Business Update
The first product to utilize Elite's abuse deterrent technology, ELI-200, has successfully completed Phase III studies. The Company believes that it will be able to file a New Drug Application (NDA) with the FDA during this calendar year. When this application is accepted by the FDA it will be granted expedited review by the FDA,the company estimates that approval could be achieved in calender Q2\2016. Shareholders will be notified when the FDA accepts the ELI-200 NDA which is estimated to be in the first or second week in Jan, 2016.
Common shares issued pursuant to the strategic alliance agreement with Epic Investments LLC.
As per the Epic Strategic Alliance, Elite is entitled to 15% of the profits achieved from the commercial sales of Epic's immediate release oxycodone tablets, for a 10 year period commencing on the date of first commercial shipment and Epic is to receive 3 million shares of Common Stock upon approval by the FDA of the ANDA.




President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.

Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755

Miscellaneous Links:

SEC Filings:

FDA website:

Clinical Trials.Gov:


  Using the industry average PE\Ratio of 15, an over exaggerated  share count of 100% of the 995M authorized shares, and a very conservative
  profit margin of 30%, Elite stands to garner an increase in share price with the launch of each abuse resistant opioid product.


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ELTP News: Current Report Filing (8-k) 09/01/2016 04:32:35 PM
ELTP News: Current Report Filing (8-k) 08/31/2016 04:19:33 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 08/19/2016 05:48:03 PM
ELTP News: Four Trending Stocks Leading Biotech Sector on Heels of Latest R&D and Innovative Drug Therapy Advancements 07/27/2016 09:00:00 AM
ELTP News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 07/21/2016 11:47:37 AM
#230575  Sticky Note I agree: ELTP is way Undervalued!!! SequestOx will Bngo 10/18/16 12:28:51 PM
#226048  Sticky Note Elite Pharmaceuticals (ELTP) is NOT a Religion !! IB_ 09/05/16 12:28:35 PM
#225095  Sticky Note THIS IS WHAT YOU NEED TO KNOW BEFORE Couch 08/31/16 08:53:18 AM
#222196  Sticky Note Freedom of Information Act Request to FDA WeeZuhl 08/17/16 07:21:46 AM
#217429  Sticky Note Here is the TRUTH about T-max-SEC-Filed! Drugdoctor 07/25/16 06:43:08 AM
#189564  Sticky Note $ELTP SequestOx and ADF Patents lasers 03/18/16 04:29:26 AM
#185967  Sticky Note The only topic here is ELTP. IH Admin [Dan] 02/23/16 09:32:46 PM
#231731   Right, and SequestOx was approved on July 14, IB_ 10/27/16 02:23:09 PM
#231730   That would be 100% correct if it wasnt namtae 10/27/16 02:17:46 PM
#231729   Gee here's what should've been highlighted. The FDA Couch 10/27/16 02:15:22 PM
#231728   Nasrat says a lot !!! There may be IB_ 10/27/16 02:13:03 PM
#231727   I avoid predictions. Ergo, I do not no2koolaid 10/27/16 02:10:22 PM
#231726   Usually is one, or one right after, but joseytheoutlawwales 10/27/16 02:09:40 PM
#231725   Heres the part that should have been highlighted namtae 10/27/16 02:08:23 PM
#231724   I would think 2-3 years what Nasrat said. stockboy 10/27/16 02:03:14 PM
#231723   LMAO; just more BS that deserves to be tossed. Couch 10/27/16 02:02:15 PM
#231722   Yeah Elite is like a chunk of coal IB_ 10/27/16 01:46:40 PM
#231721   No, this is the factual reality, Elite is no2koolaid 10/27/16 01:42:02 PM
#231720   Total BS namtae 10/27/16 01:40:26 PM
#231719   Problem with that BS is that nobody has Couch 10/27/16 01:27:35 PM
#231718   Agree!! You're exactly right Namtae namtae 10/27/16 01:07:41 PM
#231717   Gee and here I had heard there was Couch 10/27/16 12:59:17 PM
#231716   Yeah .0001 and 100k shares traded massive buying stockboy 10/27/16 12:11:12 PM
#231715   You're exactly right Namtae. Its terrible news. Its jbdiver 10/27/16 12:09:17 PM
#231714   Gee just more BS: what happened to the Couch 10/27/16 11:48:36 AM
#231713   jbdiver welcome to the $ELTP MB. Good to lasers 10/27/16 11:29:34 AM
#231712   If BP is keeping Sequest down, I wouldnt namtae 10/27/16 11:20:09 AM
#231711   $$$$$$ RUN-UP COMING TODAY; WHOOPSEY, $$$$$$$$ rocioyogi 10/27/16 11:14:58 AM
#231710   Hi Everyone. Been following you guys for about jbdiver 10/27/16 11:00:06 AM
#231709   Me too at 14. Got another 105k shares. CMDawg 10/27/16 10:48:32 AM
#231708   A decent amount of movement on low volume. Couch 10/27/16 10:47:38 AM
#231707   Everyone is a little nervous. No money CMDawg 10/27/16 10:16:33 AM
#231706   Just more BS. Couch 10/27/16 09:50:29 AM
#231705   Quite a bid and ask spread this morning. barttrab11 10/27/16 09:47:36 AM
#231701   Looks like the street has wised up to Elite namtae 10/27/16 08:57:11 AM
#231700   Gee that would be 100% true if not Couch 10/27/16 08:41:02 AM
#231699   Id be surprised if Elite is anything more namtae 10/27/16 08:08:37 AM
#231695   My guess all of that is FOS. My Couch 10/27/16 05:26:26 AM
#231693   Been hearing that BS since the .06's. Another Couch 10/27/16 05:20:34 AM
#231692   That's a pretty good synopsis and or theory stockboy 10/27/16 01:21:58 AM
#231689   My guess none of 3 solutions he came stockboy 10/27/16 01:12:33 AM
#231687   Another big red day definitely the hype is stockboy 10/27/16 01:00:04 AM
#231684   Opioids are a huge problem everywhere but this Dr PeteRose MLB 10/26/16 07:57:13 PM
#231683   Special about opioid abuse on Fox News 6pm Gman24 10/26/16 05:41:47 PM
#231682   Gee and here my .13 cent shares are Couch 10/26/16 05:08:34 PM
#231681   Gee Elite's HAL data says that is FOS Couch 10/26/16 05:07:33 PM
#231680   Time to head over to the Grand Canyon. stockboy 10/26/16 05:07:12 PM
#231679   LMAO; and here I was promised a HUGE Couch 10/26/16 05:06:00 PM
#231678   Must suck losing 10's of thousands every time stockboy 10/26/16 05:04:14 PM
#231677   Nothing to worry about defeating because no ADF stockboy 10/26/16 04:57:47 PM
#231676   Was there another warning letter issued or maybe stockboy 10/26/16 04:56:44 PM
#231675   to me the answer is obvious but I toofun 10/26/16 04:09:41 PM
#231674   Rough day today for ELTP lol namtae 10/26/16 04:05:16 PM
#231673   Lol that was figured out long ago. Amazing......... dr_lowenstein 10/26/16 04:04:51 PM
#231672   Sure, but I ask again, if it is dr_lowenstein 10/26/16 04:03:53 PM
#231671   so what in the GI tract makes one toofun 10/26/16 03:52:53 PM
#231670   The most successful long time Corporations have "trade lasers 10/26/16 03:50:59 PM